|
DE3361610D1
(en)
*
|
1982-04-07 |
1986-02-06 |
Beecham Group Plc |
Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
|
|
WO1984001960A1
(en)
*
|
1982-11-11 |
1984-05-24 |
Beecham Group Plc |
Pharmaceutically active compounds
|
|
GB8400653D0
(en)
*
|
1984-01-11 |
1984-02-15 |
Beecham Group Plc |
Conjugates
|
|
GB8430253D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5231006A
(en)
*
|
1986-10-16 |
1993-07-27 |
Behringwerke Aktiengesellschaft |
Method for the determination of plasminogen
|
|
US5256642A
(en)
*
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
JPH0296536A
(ja)
*
|
1988-09-29 |
1990-04-09 |
Green Cross Corp:The |
プラスミノゲン乾燥製剤
|
|
WO1990013640A1
(en)
*
|
1989-05-01 |
1990-11-15 |
The University Of Notre Dame Du Lac |
Methods and materials for expression of human plasminogen in a eukaryotic cell system
|
|
EP0397366A1
(en)
*
|
1989-05-09 |
1990-11-14 |
The Board Of Regents Of The University Of Oklahoma |
Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
|
|
WO1990014078A1
(en)
*
|
1989-05-17 |
1990-11-29 |
Research Corporation Technologies, Inc. |
Method and composition for the treatment of thrombosis in a mammal
|
|
AU6470590A
(en)
|
1989-10-23 |
1991-04-26 |
Smithkline Beecham Corporation |
Cyclic anti-aggregatory peptides
|
|
US5087572A
(en)
*
|
1989-12-01 |
1992-02-11 |
Genentech, Inc. |
Dna encoding human plasminogen modified at the cleavage site
|
|
US5190756A
(en)
*
|
1989-12-01 |
1993-03-02 |
Genentech, Inc. |
Methods and materials for expression of human plasminogen variant
|
|
GB8928163D0
(en)
*
|
1989-12-13 |
1990-02-14 |
Beecham Group Plc |
Novel treatment
|
|
US6458360B1
(en)
|
1990-04-25 |
2002-10-01 |
The Johns Hopkins University |
Soluble complement regulatory molecules
|
|
US5187069A
(en)
*
|
1990-08-06 |
1993-02-16 |
Henry Ford Health System |
Active site labelling of plasminogen
|
|
WO1992018139A1
(en)
*
|
1991-04-09 |
1992-10-29 |
Brigham And Women's Hospital |
Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
|
|
US5520912A
(en)
*
|
1993-07-02 |
1996-05-28 |
Immuno Aktiengesellschaft |
Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
|
|
DE4411143C2
(de)
*
|
1994-03-30 |
1996-08-01 |
Immuno Ag |
Thrombosemittel
|
|
US5760028A
(en)
*
|
1995-12-22 |
1998-06-02 |
The Dupont Merck Pharmaceutical Company |
Integrin receptor antagonists
|
|
US6004955A
(en)
*
|
1996-08-15 |
1999-12-21 |
Dupont Pharmaceuticals Company |
Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
|
|
HRP980334A2
(en)
|
1997-06-19 |
1999-04-30 |
Mimi Lifen Quan |
INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
|
|
CA2376245A1
(en)
*
|
1999-07-29 |
2001-02-08 |
Dyax Corp. |
Binding moieties for fibrin
|
|
US6388073B1
(en)
|
2000-07-26 |
2002-05-14 |
Shire Us Inc. |
Method for the manufacture of anagrelide
|
|
KR20010000669A
(ko)
*
|
2000-10-12 |
2001-01-05 |
김기환 |
스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
|
|
US6984373B2
(en)
*
|
2000-12-23 |
2006-01-10 |
Dyax Corp. |
Fibrin binding moieties useful as imaging agents
|
|
EP1427415B1
(en)
|
2001-09-21 |
2009-08-12 |
Brystol-Myers Squibb Company |
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
|
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US7700608B2
(en)
*
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
|
US20060030574A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Shire Holdings Ag |
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
|
|
JP5236293B2
(ja)
|
2005-01-13 |
2013-07-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
Ｘｉａ因子阻害剤としての置換ビアリール化合物
|
|
AU2006206611A1
(en)
|
2005-01-19 |
2006-07-27 |
Bristol-Myers Squibb Company |
2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
|
|
DE602006020871D1
(de)
|
2005-06-27 |
2011-05-05 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
|
|
US7728008B2
(en)
|
2005-06-27 |
2010-06-01 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US7714002B2
(en)
|
2005-06-27 |
2010-05-11 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
WO2007002635A2
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
WO2007146719A2
(en)
|
2006-06-08 |
2007-12-21 |
Bristol-Myers Squibb Company |
2-aminocarbonylphenylamino-2-phenylacetamides as factor viia inhibitors useful as anticoagulants
|
|
US7960569B2
(en)
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US8304420B2
(en)
|
2006-11-28 |
2012-11-06 |
Shire Llc |
Substituted quinazolines for reducing platelet count
|
|
US7910597B2
(en)
*
|
2006-11-28 |
2011-03-22 |
Shire Llc |
Substituted quinazolines
|
|
EP2102189B1
(en)
|
2006-12-15 |
2015-07-29 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
|
EP2152664B1
(en)
|
2007-06-13 |
2014-09-03 |
Bristol-Myers Squibb Company |
Dipeptide analogs as coagulation factor inhibitors
|
|
US20090130017A1
(en)
*
|
2007-11-19 |
2009-05-21 |
Searete Llc |
Targeted short-lived drug delivery
|
|
CN102099340A
(zh)
|
2008-05-19 |
2011-06-15 |
先灵公司 |
作为因子ixa抑制剂的杂环化合物
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
WO2011017296A1
(en)
|
2009-08-04 |
2011-02-10 |
Schering Corporation |
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
|
CA2789622C
(en)
|
2010-02-11 |
2018-04-03 |
Bristol-Myers Squibb Company |
Macrocycles as factor xia inhibitors
|
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子ｘｉａ抑制劑之新穎巨環化合物
|
|
TW201319068A
(zh)
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
|
|
WO2013056034A1
(en)
|
2011-10-14 |
2013-04-18 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
SI2766346T1
(sl)
|
2011-10-14 |
2017-05-31 |
Bristol-Myers Squibb Company |
Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
|
|
EP2899183B1
(en)
|
2011-10-14 |
2018-09-19 |
Bristol-Myers Squibb Company |
Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
|
|
GEP201706656B
(en)
|
2011-11-11 |
2017-04-25 |
Pfizer |
2-thiopyrimidinones
|
|
SG11201405477XA
(en)
|
2012-04-06 |
2014-11-27 |
Pfizer |
Diacylglycerol acyltransferase 2 inhibitors
|
|
LT2882734T
(lt)
|
2012-08-03 |
2016-12-12 |
Bristol-Myers Squibb Company |
Dihidropiridonai, kaip xia faktoriaus slopikliai
|
|
PT2880026T
(pt)
|
2012-08-03 |
2017-05-03 |
Bristol Myers Squibb Co |
Dihidropiridona p1 como inibidores de fator xia
|
|
EP2978751B1
(en)
|
2013-03-25 |
2018-12-05 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
|
|
JP6348582B2
(ja)
|
2013-10-09 |
2018-06-27 |
ファイザー・インク |
プロスタグランジンｅｐ３受容体の拮抗薬
|
|
NO2760821T3
(cs)
|
2014-01-31 |
2018-03-10 |
|
|
|
KR20240017118A
(ko)
|
2014-01-31 |
2024-02-06 |
브리스톨-마이어스 스큅 컴퍼니 |
인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
|
|
EP3119757B1
(en)
|
2014-03-17 |
2018-05-16 |
Pfizer Inc |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
|
WO2015150995A1
(en)
|
2014-04-04 |
2015-10-08 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
|
|
WO2015160636A1
(en)
|
2014-04-16 |
2015-10-22 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
|
NO2721243T3
(cs)
|
2014-10-01 |
2018-10-20 |
|
|
|
MA42035A
(fr)
|
2015-05-05 |
2018-03-14 |
Pfizer |
2-thiopyrimidinones
|
|
ES2832893T3
(es)
|
2015-06-17 |
2021-06-11 |
Pfizer |
Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
US10676477B2
(en)
|
2015-07-29 |
2020-06-09 |
Bristol-Myers Squibb Company |
Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
|
|
CN108137549B
(zh)
|
2015-08-05 |
2021-07-20 |
百时美施贵宝公司 |
取代的甘氨酸衍生的fxia抑制剂
|
|
RS61719B1
(sr)
|
2015-08-27 |
2021-05-31 |
Pfizer |
Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
|
|
WO2017151746A1
(en)
|
2016-03-02 |
2017-09-08 |
Bristol-Myers Squibb Company |
Diamide macrocycles having factor xia inhibiting activity
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
BR112021003039A2
(pt)
|
2018-08-31 |
2021-05-18 |
Pfizer Inc. |
combinações para o tratamento de nash/nafld e doenças relacionadas
|
|
US12611401B2
(en)
|
2019-05-20 |
2026-04-28 |
Pfizer Inc. |
Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
|
|
ES3048448T3
(en)
|
2020-07-22 |
2025-12-10 |
Janssen Pharmaceutica Nv |
Compounds useful as factor xia inhibitors
|
|
WO2023026180A1
(en)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|